| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7029694 | ABBVIE | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US8241662 | ABBVIE | Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US10272061 | ABBVIE | Compositions and methods for unoccluded transdermal oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US7179483 | ABBVIE | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(3 years ago) | |
| US10449173 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(5 years from now) | |
| US9259388 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(5 years from now) | |
| US8920392 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Mar, 2031
(6 years from now) | |
Gelnique is owned by Abbvie.
Gelnique contains Oxybutynin Chloride.
Gelnique has a total of 7 drug patents out of which 4 drug patents have expired.
Expired drug patents of Gelnique are:
- US7029694
- US8241662
- US10272061
- US7179483
Gelnique was authorised for market use on 27 January, 2009.
Gelnique is available in gel;transdermal dosage forms.
Gelnique can be used as treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel, treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency or urge incontinence, treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence, treatment of overactive bladder by application of oxybutynin chloride gel to skin.
The generics of Gelnique are possible to be released after 26 March, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 27, 2012 |
Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient
Market Authorisation Date: 27 January, 2009
Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence; Treatment of patients with an overactive bladder with symptoms of urinary frequency,...
Dosage: GEL;TRANSDERMAL
GELNIQUE family patents
